Skip to main content
Quest Diagnostics

Analytical Validation and Performance Characteristics of a 48-gene Next-generation Sequencing Panel for Detecting Potentially Actionable Genomic Alterations in Myeloid Neoplasms

Analytical Validation and Performance Characteristics of a 48-gene Next-generation Sequencing Panel for Detecting Potentially Actionable Genomic Alterations in Myeloid Neoplasms

Authors: Rosenthal SH, Gerasimova A, Ma C, Li HR, Grupe A, Chong H, Acab A, Smolgovsky A, Owen R, Elzinga C, Chen R, Sugganth D, Freitas T, Graham J, Champion K, Bhattacharya A, Racke F, Lacbawan F.

Citation: PLoS One. 2021 Apr 28;16(4):e0243683. doi: 10.1371/journal.pone.0243683. eCollection 2021.

Specialties: Oncology, Genetics

Download key summary

Related content

On-Demand Webinar
Hemepath Master Class Myeloid Neoplasms MPN MDS AML
Test FAQ
Myeloproliferative Neoplasm Diagnosis Molecular Evaluation
On-Demand Webinar
Quality Considerations for Mobile Blood Draws and Specimen Collections: Supporting Decentralized Studies and Trials

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.